Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HL07/WBP297 in RAS wild-type metastatic colorectal cancer
CTR20190662Phase 2Active
- Sponsor
- Hualan Ankang Biotechnology
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HL07/WBP297 in colorectal cancer (CRC), sponsored by Hualan Ankang Biotechnology. Started Dec 2019; status: active.
02
Drugs
HL07/WBP297
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20190662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190662.